Bristol-Myers Squibb (NYSE:BMY) Shares Up 0.3%

Bristol-Myers Squibb (NYSE:BMY - Get Free Report)'s share price shot up 0.3% during trading on Tuesday . The stock traded as high as $44.20 and last traded at $44.02. 2,495,695 shares were traded during trading, a decline of 84% from the average session volume of 15,682,183 shares. The stock had previously closed at $43.90.

Wall Street Analyst Weigh In

A number of research firms recently weighed in on BMY. Barclays lowered their price objective on shares of Bristol-Myers Squibb from $51.00 to $43.00 and set an "equal weight" rating for the company in a research note on Friday, April 26th. Societe Generale lowered shares of Bristol-Myers Squibb from a "buy" rating to a "hold" rating in a research note on Monday, March 11th. Wells Fargo & Company raised their target price on shares of Bristol-Myers Squibb from $51.00 to $52.00 and gave the company an "equal weight" rating in a research note on Thursday, April 18th. William Blair reaffirmed a "market perform" rating on shares of Bristol-Myers Squibb in a research report on Monday, April 1st. Finally, StockNews.com cut Bristol-Myers Squibb from a "strong-buy" rating to a "buy" rating in a research report on Monday, April 15th. One research analyst has rated the stock with a sell rating, fifteen have assigned a hold rating and four have issued a buy rating to the company's stock. According to data from MarketBeat.com, the company presently has a consensus rating of "Hold" and a consensus target price of $60.00.

Bristol-Myers Squibb Trading Up 0.3 %

The company has a fifty day moving average of $50.11 and a 200-day moving average of $50.48. The company has a market capitalization of $89.27 billion, a price-to-earnings ratio of -14.21, a PEG ratio of 14.82 and a beta of 0.45. The company has a current ratio of 1.11, a quick ratio of 0.99 and a debt-to-equity ratio of 2.99.

Bristol-Myers Squibb (NYSE:BMY - Get Free Report) last issued its quarterly earnings results on Thursday, April 25th. The biopharmaceutical company reported ($4.40) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($4.53) by $0.13. Bristol-Myers Squibb had a positive return on equity of 8.83% and a negative net margin of 13.50%. The firm had revenue of $11.87 billion for the quarter, compared to analyst estimates of $11.45 billion. During the same period in the previous year, the company posted $2.05 earnings per share. The business's revenue was up 4.7% on a year-over-year basis. As a group, equities research analysts anticipate that Bristol-Myers Squibb will post 0.59 earnings per share for the current fiscal year.

Bristol-Myers Squibb Dividend Announcement

The firm also recently declared a quarterly dividend, which was paid on Wednesday, May 1st. Stockholders of record on Friday, April 5th were paid a $0.60 dividend. This represents a $2.40 annualized dividend and a dividend yield of 5.45%. The ex-dividend date of this dividend was Thursday, April 4th. Bristol-Myers Squibb's dividend payout ratio is currently -77.42%.

Institutional Trading of Bristol-Myers Squibb

A number of hedge funds have recently bought and sold shares of BMY. OFI Invest Asset Management purchased a new position in Bristol-Myers Squibb during the third quarter worth approximately $25,000. Milestone Investment Advisors LLC purchased a new stake in shares of Bristol-Myers Squibb in the third quarter valued at about $27,000. Northwest Financial Advisors acquired a new stake in Bristol-Myers Squibb during the fourth quarter worth about $27,000. Blue Bell Private Wealth Management LLC raised its stake in Bristol-Myers Squibb by 61.5% during the third quarter. Blue Bell Private Wealth Management LLC now owns 525 shares of the biopharmaceutical company's stock worth $30,000 after purchasing an additional 200 shares during the period. Finally, Accordant Advisory Group Inc acquired a new position in Bristol-Myers Squibb in the 1st quarter valued at about $31,000. Institutional investors and hedge funds own 76.41% of the company's stock.

About Bristol-Myers Squibb

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, and neuroscience diseases. The company's products include Eliquis for reduction in risk of stroke/systemic embolism in non-valvular atrial fibrillation, and for the treatment of DVT/PE; Opdivo for various anti-cancer indications, including bladder, blood, CRC, head and neck, RCC, HCC, lung, melanoma, MPM, stomach and esophageal cancer; Pomalyst/Imnovid for multiple myeloma; Orencia for active rheumatoid arthritis and psoriatic arthritis; and Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia.